Recent Updates
Recently added Catalysts

SYR-322-MET

Phase 3

Clinical Pharmacology | Small molecule | Other |Takeda Pharmaceutical Company Limited|Last Updated: Sep 21, 2023

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedCONTROLLED
Total Trials1
Total Enrollment12

FDA Designations

No designations recorded

Clinical trial landscape

SYR-322-MET · 1 trial · 1 indication

Phase 3 1
NCT02276274Effect of Food on the Pharmacokinetics of Single Oral Dose Administration of a Fixed-Dose Combination of SYR-322 and Metformin Hydrochloride in Healthy Adult Male SubjectsClinical Pharmacology
COMPLETED12 Analytics
PHASE3COMPLETED
Effect of Food on the Pharmacokinetics of Single Oral Dose Administration of a Fixed-Dose Combination of SYR-322 and Metformin Hydrochloride in Healthy Adult Male Subjects
Clinical Pharmacology
NCT0227627412
Unlock trial analytics

Study Endpoints

Primary Endpoints

AUC (0-72): Area Under the Plasma Concentration-time Curve From Time 0 to 72 Hours Postdose for Unchanged SYR-322 (SYR-322Z)
3 hours prior to administration (predose) and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, and 72 hours postdose

AUC (0-72) is measure of area under the curve from time 0 to 72 hours post dose.

AUC (0-tlqc): Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for SYR-322Z
3 hours prior to administration (predose) and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, and 72 hours postdose

AUC (0-tlqc) is a measure of total plasma exposure to the drug from Time 0 to Time of the Last Quantifiable Concentration (AUC \[0-tlqc\]).

Cmax: Maximum Observed Plasma Concentration for SYR-322Z
3 hours prior to administration (predose) and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, and 72 hours postdose

Maximum observed plasma concentration (Cmax) is the peak plasma concentration of a drug after administration, obtained directly from the plasma concentration-time curve.

Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for SYR-322Z
3 hours prior to administration (predose) and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, and 72 hours postdose

Tmax: Time to reach the maximum plasma concentration (Cmax), equal to time (hours) to Cmax.

AUC (0-inf): Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for SYR-322Z
3 hours prior to administration (predose) and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, and 72 hours postdose

AUC (0-inf) is a measure of total plasma exposure to the drug from time zero extrapolated to infinity.

Apparent Terminal Elimination Rate Constant (λz) for SYR-322Z
3 hours prior to administration (predose) and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, and 72 hours postdose

Terminal elimination rate constant, calculated as the negative of the slope of the log-linear regression of the natural logarithm concentration-time curve during the terminal phase.

Terminal Phase Elimination Half-life (T1/2) for SYR-322Z
3 hours prior to administration (predose) and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, and 72 hours postdose

Terminal phase elimination half-life (T1/2) is the time required for half of the drug to be eliminated from the plasma.

Apparent Clearance After Extra Vascular Administration (CL/F) for SYR-322Z
3 hours prior to administration, and at 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48 and 72 hours after administration

CL/F is apparent clearance of the drug from the plasma, calculated as the drug dose divided AUC (0-inf), expressed in liter/hour (L/hr).

Mean Residence Time (MRT) for SYR-322Z
3 hours prior to administration (predose) and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, and 72 hours postdose

Mean residence time (MRT) calculated as area under the first moment plasma concentration-time curve (AUMC \[0-inf\]) divided by AUC (0-inf). (AUMC \[0-inf\]) is the area under the first moment plasma concentration-time curve from time 0 to infinity.

MRT (0-tlqc): Mean Residence Time From Time 0 to Time of the Last Quantifiable Concentration (Tlqc) for SYR-322Z
3 hours prior to administration (predose) and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, and 72 hours postdose

MRT (0-tlqc) is a measure of the mean residence time from time 0 to time of the last quantifiable concentration (tlqc) calculated as MRT (0-tlqc) =AUMC (0-tlqc)/AUC (0-tlqc). AUMC (0-tlqc) is the area under the first moment plasma concentration-time curve from time 0 to time of the last quantifiable concentration (tlqc), calculated using the linear trapezoidal rule.

AUC (0-72): Area Under the Plasma Concentration-time Curve From Time 0 to 72 Hours Post Dose for SYR-322 Metabolites M-I and M-II
3 hours prior to administration (predose) and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, and 72 hours postdose

AUC (0-72) is measure of area under the curve from time 0 to 72 hours post dose.

AUC (0-tlqc): Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for SYR-322 Metabolites M-I and M-II
3 hours prior to administration (predose) and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, and 72 hours postdose

AUC (0-tlqc) is a measure of total plasma exposure to the drug from Time 0 to Time of the Last Quantifiable Concentration (AUC \[0-tlqc\]).

MRT (0-tlqc): Mean Residence Time From Time 0 to Time of the Last Quantifiable Concentration (Tlqc) for SYR-322 Metabolites M-I and M-II
3 hours prior to administration (predose) and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, and 72 hours postdose

MRT (0-tlqc) is a measure of the mean residence time from time 0 to time of the last quantifiable concentration (tlqc) calculated as MRT (0-tlqc) =AUMC (0-tlqc)/AUC (0-tlqc). AUMC (0-tlqc) is the area under the first moment plasma concentration-time curve from time 0 to time of the last quantifiable concentration (tlqc), calculated using the linear trapezoidal rule.

Cmax: Maximum Observed Plasma Concentration for SYR-322 Metabolites M-I and M-II
3 hours prior to administration (predose) and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, and 72 hours postdose

Maximum observed plasma concentration (Cmax) is the peak plasma concentration of a drug after administration, obtained directly from the plasma concentration-time curve.

Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for SYR-322 Metabolites M-I and M-II
3 hours prior to administration (predose) and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, and 72 hours postdose

Tmax: Time to reach the maximum plasma concentration (Cmax), equal to time (hours) to Cmax.

AUC (0-inf): Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for SYR-322 Metabolites M-I and M-II
3 hours prior to administration (predose) and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, and 72 hours postdose

AUC (0-inf) is a measure of total plasma exposure to the drug from time zero extrapolated to infinity.

Apparent Terminal Elimination Rate Constant (λz) for SYR-322 Metabolites M-I and M-II
3 hours prior to administration (predose) and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, and 72 hours postdose

Terminal elimination rate constant, calculated as the negative of the slope of the log-linear regression of the natural logarithm concentration-time curve during the terminal phase.

Terminal Phase Elimination Half-life (T1/2) for SYR-322 Metabolites M-I and M-II
3 hours prior to administration (predose) and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, and 72 hours postdose

Terminal phase elimination half-life (T1/2) is the time required for half of the drug to be eliminated from the plasma.

Mean Residence Time (MRT) for SYR-322 Metabolites M-I and M-II
3 hours prior to administration (predose) and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, and 72 hours postdose

Mean residence time (MRT) calculated as area under the first moment plasma concentration-time curve (AUMC \[0-inf\]) divided by AUC (0-inf). AUMC (0-inf) is the area under the first moment plasma concentration-time curve from time 0 to infinity.

AUC (0-48): Area Under the Plasma Concentration-time Curve From Time 0 to 48 Hours Postdose for Metformin
3 hours prior to administration (predose) and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, and 48 hours postdose

AUC (0-48) is measure of area under the curve from time 0 to 48 hours post dose.

AUC (0-tlqc): Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Metformin
3 hours prior to administration (predose) and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, and 48 hours postdose

AUC (0-tlqc) is a measure of total plasma exposure to the drug from Time 0 to Time of the Last Quantifiable Concentration (AUC \[0-tlqc\]).

MRT (0-tlqc): Mean Residence Time From Time 0 to Time of the Last Quantifiable Concentration (Tlqc) for Metformin
3 hours prior to administration (predose) and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, and 48 hours postdose

MRT (0-tlqc) is a measure of the mean residence time from time 0 to time of the last quantifiable concentration (tlqc) calculated as MRT (0-tlqc) =AUMC (0-tlqc)/AUC (0-tlqc). AUMC (0-tlqc) is the area under the first moment plasma concentration-time curve from time 0 to time of the last quantifiable concentration (tlqc), calculated using the linear trapezoidal rule.

Cmax: Maximum Observed Plasma Concentration for Metformin
3 hours prior to administration (predose) and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, and 48 hours postdose

Maximum observed plasma concentration (Cmax) is the peak plasma concentration of a drug after administration, obtained directly from the plasma concentration-time curve.

Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for Metformin
3 hours prior to administration (predose) and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, and 48 hours postdose

Tmax: Time to reach the maximum plasma concentration (Cmax), equal to time (hours) to Cmax.

AUC (0-inf): Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for Metformin
3 hours prior to administration (predose) and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, and 48 hours postdose

AUC (0-inf) is a measure of total plasma exposure to the drug from time zero extrapolated to infinity.

Apparent Terminal Elimination Rate Constant (λz) for Metformin
3 hours prior to administration (predose) and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, and 48 hours postdose

Terminal elimination rate constant, calculated as the negative of the slope of the log-linear regression of the natural logarithm concentration-time curve during the terminal phase.

Terminal Phase Elimination Half-life (T1/2) for Metformin
3 hours prior to administration (predose) and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, and 48 hours postdose

Terminal phase elimination half-life (T1/2) is the time required for half of the drug to be eliminated from the plasma.

Apparent Clearance After Extra Vascular Administration (CL/F) for Metformin
3 hours prior to administration (predose) and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, and 48 hours postdose

CL/F is apparent clearance of the drug from the plasma, calculated as the drug dose divided AUC (0-inf), expressed in L/hr.

Mean Residence Time (MRT) for Metformin
3 hours prior to administration (predose) and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, and 48 hours postdose

Mean residence time (MRT) calculated as area under the first moment plasma concentration-time curve (AUMC \[0-inf\]) divided by AUC (0-inf). AUMC (0-inf) is the area under the first moment plasma concentration-time curve from time 0 to infinity.

Urinary Excretion Ratio of SYR-322Z From 0 to 12 Hours Postdose
0 to 12 hours postdose

Cumulative urinary excretion ratio of unchanged SYR-322 was calculated as the percentage of SYR-322 dose.

Urinary Excretion Ratio of SYR-322Z From 0 to 24 Hours Postdose
0 to 24 hours postdose

Cumulative urinary excretion ratio of unchanged SYR-322 was calculated as the percentage of SYR-322 dose.

Urinary Excretion Ratio of SYR-322Z From 0 to 48 Hours Postdose
0 to 48 hours postdose

Cumulative urinary excretion ratio of unchanged SYR-322 was calculated as the percentage of SYR-322 dose.

Urinary Excretion Ratio of SYR-322Z From 0 to 72 Hours Postdose
0 to 72 hours postdose

Cumulative urinary excretion ratio of unchanged SYR-322 was calculated as the percentage of SYR-322 dose.

Urinary Excretion Ratio of SYR-322 Metabolites M-I and M-II From 0 to 12 Hours Postdose
0 to 12 hours postdose

Cumulative urinary excretion ratio of SYR-322 metabolites M-I and M-II was calculated as the percentage of SYR-322 dose.

Urinary Excretion Ratio of SYR-322 Metabolites M-I and M-II From 0 to 24 Hours Postdose
0 to 24 hours post dose

Cumulative urinary excretion ratio of SYR-322 metabolites M-I and M-II was calculated as the percentage of SYR-322 dose.

Urinary Excretion Ratio of SYR-322 Metabolites M-I and M-II From 0 to 48 Hours Postdose
0 to 48 hours postdose

Cumulative urinary excretion ratio of SYR-322 metabolites M-I and M-II was calculated as the percentage of SYR-322 dose.

Urinary Excretion Ratio of SYR-322 Metabolites M-I and M-II From 0 to 72 Hours Postdose
0 to 72 hours postdose

Cumulative urinary excretion ratio of SYR-322 metabolites M-I and M-II was calculated as the percentage of SYR-322 dose.

Urinary Excretion Ratio of Metformin From Time 0 to 12 Hours Postdose
0 to 12 hours postdose

Cumulative urinary excretion ratio of metformin was calculated as the percentage of metformin dose.

Urinary Excretion Ratio of Metformin From 0 to 24 Hours Postdose
0 to 24 hours postdose

Cumulative urinary excretion ratio of metformin was calculated as the percentage of metformin dose.

Urinary Excretion Ratio of Metformin From 0 to 48 Hours Postdose
0 to 48 hours postdose

Cumulative urinary excretion ratio of metformin was calculated as the percentage of metformin dose.

CLr: Renal Clearance of SYR-322Z
3 hours prior to administration (predose) and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, and 72 hours postdose

CLr is a measure of apparent clearance of the drug from the urine. The clearance is the rate at which waste substances are cleared from the blood.

CLr: Renal Clearance of Metformin
3 hours prior to administration (predose) and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, and 48 hours postdose

CLr is a measure of apparent clearance of the drug from the urine.

Secondary Endpoints

Inhibition Rate of Dipeptidyl-peptidase-4 (DPP-4) Activity
3 hours prior to administration (predose) and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 24 hours postdose
DPP-4 Activity
3 hours prior to administration (predose) and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 24 hours postdose
AUC (0-24): Area Under the Inhibition Rate of Plasma DPP-4 Activity-time Curve From Time 0 to 24 Hours
3 hours prior to administration (predose) and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 24 hours postdose
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingNONE
ModelCROSSOVER
PurposeBASIC_SCIENCE

Treatment Arms

ArmTypeDescription
Fasted dosing followed by fed dosingEXPERIMENTALOral administration
Fed dosing followed by fasted dosingEXPERIMENTALOral administration

Interventions

NameTypeDescription
SYR-322-METDRUGOral administration of SYR-322-MET
Unlock Study Design Details

Eligibility Criteria

Age Range20 Years to 35 Years
SexMALE
Healthy VolunteersYes
Study Sites1

Inclusion Criteria: 1. In the opinion of the investigator or subinvestigator, the subject is capable of understanding and complying with protocol requirements. 2. The subject signs and dates a written, informed consent form prior to the initiation of any study procedures. 3. The subject is a Japane...

Countries:Japan
Unlock Eligibility Criteria

Frequently asked questions about SYR-322-MET

What is SYR-322-MET used for?

SYR-322-MET is a fixed-dose combination of SYR-322 and metformin hydrochloride being studied for clinical pharmacology purposes. It is an investigational small molecule in Phase 3 development by Takeda Pharmaceutical Company Limited. The drug is not approved and remains in clinical development.

Who makes SYR-322-MET?

SYR-322-MET is being developed by Takeda Pharmaceutical Company Limited, traded as TAK. The company is conducting clinical trials to evaluate the drug's pharmacokinetics. As of the latest data, SYR-322-MET is in Phase 3 development and is not yet approved.

What phase is SYR-322-MET in?

SYR-322-MET is in Phase 3 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The drug is being studied for clinical pharmacology, with one completed Phase 3 trial involving healthy volunteers.

What clinical trials is SYR-322-MET in?

SYR-322-MET has one completed clinical trial, NCT02276274, titled 'Effect of Food on the Pharmacokinetics of Single Oral Dose Administration of a Fixed-Dose Combination of SYR-322 and Metformin Hydrochloride in Healthy Adult Male Subjects.' This Phase 3 study enrolled 12 healthy male participants in Japan.

Is SYR-322-MET the same as a combination of SYR-322 and metformin?

Yes, SYR-322-MET is a fixed-dose combination of SYR-322 and metformin hydrochloride. The drug is being studied to assess the effect of food on its pharmacokinetics after a single oral dose. It is an investigational small molecule in Phase 3 development by Takeda.